Trial Profile
A Phase 1/2 Study of Derazantinib in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma With FGFR2 Gene Fusion
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Derazantinib (Primary)
- Indications Cholangiocarcinoma; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Basilea Pharmaceutica
- 12 Oct 2020 Results of pooled analysis from two clinical studies and an expanded access program (n=23), presented in a Basilea Pharmaceutica Ltd media release.
- 12 Oct 2020 According to a Basilea Pharmaceutica Ltd media release, results of pooled analysis from two clinical studies and an expanded access program (n=23) was presented at the Molecular Analysis for Precision Oncology (MAP) Virtual Congress 2020 organized by the European Society for Medical Oncology (ESMO).
- 30 Sep 2019 According to a Basilea Pharmaceutica media release, results of post hoc analysis were presented at the Annual Congress of the European Society for Medical Oncology (ESMO) 2019.